Recently, the CheckMate-649 study showed that nivolumab, an anti-PD-1-antibody, in combination with chemotherapy significantly improved overall survival (98.4% CI 0.59–0.86; HR 0.71) and progression-free survival (98% CI 0.56–0.81; HR 0.68) vs. chemotherapy alone in patients with a PD-L1 CPS ≥ 5 and advanced gastric, esophagogastric junction, and esophageal adenocarcinoma (Janjigian et al. 2021). Here, CD274 is linked to esophageal adenocarcinoma.